| Display title | Chemistry:Vatalanib |
| Default sort key | Vatalanib |
| Page length (in bytes) | 7,473 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 229319 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>QCDvac |
| Date of page creation | 22:30, 5 February 2024 |
| Latest editor | imported>QCDvac |
| Date of latest edit | 22:30, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active... |
